7 followers
Rheumatology: JAK inhibitor peficitinib phase IIb two-year open-label extension showing safety and efficacy tempered by 52.2% completion rate - https://t.co/xpvFySdoVI
Rheumatology: JAK inhibitor peficitinib phase IIb two-year open-label extension showing safety and efficacy tempered by 52.2% completion rate - https://t.co/xpvFySdoVI
Just published: "Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study" #RheumatoidArthritis. Read the full paper here: https://t.co/v8ij8ZBgGN https://t.co/2pOr1zTaZy